IT1250722B - Oligonucleotidi antisenso - Google Patents
Oligonucleotidi antisensoInfo
- Publication number
- IT1250722B IT1250722B ITMI912117A ITMI912117A IT1250722B IT 1250722 B IT1250722 B IT 1250722B IT MI912117 A ITMI912117 A IT MI912117A IT MI912117 A ITMI912117 A IT MI912117A IT 1250722 B IT1250722 B IT 1250722B
- Authority
- IT
- Italy
- Prior art keywords
- modifications
- antisense oligonucleotides
- concerns
- antisense
- ability
- Prior art date
Links
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 4
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 3
- 238000012986 modification Methods 0.000 abstract 4
- 230000004048 modification Effects 0.000 abstract 4
- 101000574060 Homo sapiens Progesterone receptor Proteins 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000009396 hybridization Methods 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invenzione riguarda un oligonucleotide antisenso che comprende una sequenza di nucleotidi che è caratterizzata dalla sua possibilità di ibridare in condizioni di ibridazione drastiche fino ad una parte della sequenza mRNA del recettore di progesterone umano e inoltre è caratterizzata dalla sua possibilità di bloccare la sintesi del recettore del progesterone umano, e sue modificazioni, riguarda un procedimento per la preparazione di tali oligonucleotici antisenso e di tali modificazioni riguarda composizioni farmaceutiche contenenti tali oligonucleotidi antisenso e tali modificazioni e riguarda l'uso di questi oligonucleotidi antisenso e di loro modificazioni come sostanza terapeutica.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI912117A IT1250722B (it) | 1991-07-30 | 1991-07-30 | Oligonucleotidi antisenso |
| PCT/EP1992/001745 WO1993003053A1 (en) | 1991-07-30 | 1992-07-29 | Antisense oligonucleotides |
| EP92916147A EP0605437A1 (en) | 1991-07-30 | 1992-07-29 | Antisense oligonucleotides |
| AU23872/92A AU2387292A (en) | 1991-07-30 | 1992-07-29 | Antisense oligonucleotides |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI912117A IT1250722B (it) | 1991-07-30 | 1991-07-30 | Oligonucleotidi antisenso |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| ITMI912117A0 ITMI912117A0 (it) | 1991-07-30 |
| ITMI912117A1 ITMI912117A1 (it) | 1993-01-30 |
| IT1250722B true IT1250722B (it) | 1995-04-21 |
Family
ID=11360462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ITMI912117A IT1250722B (it) | 1991-07-30 | 1991-07-30 | Oligonucleotidi antisenso |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0605437A1 (it) |
| AU (1) | AU2387292A (it) |
| IT (1) | IT1250722B (it) |
| WO (1) | WO1993003053A1 (it) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1043045C (zh) * | 1994-04-14 | 1999-04-21 | 同济医科大学 | 抑制内皮素生成的寡核苷酸及其应用 |
| EP1982183B9 (en) | 2006-01-19 | 2012-12-12 | Lattec I/S | Dry stick device and method for determining an analyte in a sample |
| CA2637705C (en) | 2006-01-19 | 2013-10-29 | Lattec I/S | A novel dry stick device construction and method for determining an analyte in a sample using said dry stick device |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3907562A1 (de) * | 1989-03-09 | 1990-09-13 | Bayer Ag | Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung |
| FR2651130B1 (fr) * | 1989-08-23 | 1991-12-13 | Roussel Uclaf | Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques. |
-
1991
- 1991-07-30 IT ITMI912117A patent/IT1250722B/it active IP Right Grant
-
1992
- 1992-07-29 WO PCT/EP1992/001745 patent/WO1993003053A1/en not_active Ceased
- 1992-07-29 AU AU23872/92A patent/AU2387292A/en not_active Abandoned
- 1992-07-29 EP EP92916147A patent/EP0605437A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0605437A1 (en) | 1994-07-13 |
| ITMI912117A0 (it) | 1991-07-30 |
| ITMI912117A1 (it) | 1993-01-30 |
| AU2387292A (en) | 1993-03-02 |
| WO1993003053A1 (en) | 1993-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0002296A2 (hu) | Sertralinsók és a sertralin elnyújtott felszabadulását biztosító dózisformák | |
| AU1313095A (en) | Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role | |
| DE69615704D1 (de) | Bioadhesive feste arzneimittelform | |
| PT1162982E (pt) | Utilizacao de oligonucleotidos estabilizados pata a preparacao de um meicamento com accao anti-tumor | |
| IL133585A0 (en) | Soluble prodrugs of paclitaxel | |
| EP0994850B1 (en) | Inhibition of hiv-1 replication using oligocarbamate derivatives | |
| ATE235907T1 (de) | Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen | |
| EP0673252A4 (en) | ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES TO THE DOPAMIN RECEPTOR RNA MESSENGER FOR DIAGNOSING AND TREATING NEUROLOGICAL CONDITIONS. | |
| AU3295700A (en) | Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same | |
| CA2023899A1 (fr) | Sequence d'oligonucleotides anti-sens, anti-arn messager du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques | |
| IL147149A0 (en) | Novel diphenyl-piperidine derivate | |
| BG104357A (en) | Derivatives of cyclopentene used as motiline receptor antagonists | |
| KR950703359A (ko) | 임신치료를 위한 파라소면(parathormone), 그 생물학적 활성 프래그먼트(fragment) 및 관련 펩티드(peptide)의 용도 | |
| BG101427A (en) | Competitive progesterone antagonists for regulating female fertility as required | |
| HUP0100044A1 (hu) | A humán Ha-ras gén egy szakaszával komplementer, módosított antiszensz oligonukleotidok | |
| HUP9801689A2 (hu) | Lizozim dimerek új alkalmazása | |
| TR200101083T2 (tr) | (7alfa,17alfa)-17-hidroksi- 7-metil-19-nor-17-pregn-5 (10)-en-20-in-3-on içeren yüksek saflıkta bileşim. | |
| ATE384133T1 (de) | Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen | |
| AU3881095A (en) | Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient | |
| WO1994028176A3 (en) | Bc200 rna, probes therefor and use thereof | |
| YU56702A (sh) | Korišćenje fsh za lečenje neplodnosti | |
| HUP0004577A1 (hu) | Kationos nukleinsav transzfekciós ágensek új csoportja | |
| IT1271684B (it) | Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi | |
| MY103584A (en) | 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it | |
| ATE275576T1 (de) | Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 0001 | Granted | ||
| TA | Fee payment date (situation as of event date), data collected since 19931001 |
Effective date: 19970730 |